KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Operating Margin (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Operating Margin for 15 consecutive years, with 1.86% as the latest value for Q4 2025.

  • On a quarterly basis, Operating Margin fell 1415.0% to 1.86% in Q4 2025 year-over-year; TTM through Dec 2025 was 8.66%, a 2100.0% decrease, with the full-year FY2025 number at 8.66%, down 2100.0% from a year prior.
  • Operating Margin was 1.86% for Q4 2025 at Supernus Pharmaceuticals, up from 31.35% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 24.14% in Q2 2021 to a low of 31.35% in Q3 2025.
  • A 5-year average of 4.84% and a median of 4.56% in 2021 define the central range for Operating Margin.
  • Peak YoY movement for Operating Margin: soared 2638bps in 2024, then tumbled -5460bps in 2025.
  • Supernus Pharmaceuticals' Operating Margin stood at 3.83% in 2021, then surged by 435bps to 20.52% in 2022, then plummeted by -103bps to 0.61% in 2023, then surged by 2128bps to 12.29% in 2024, then plummeted by -115bps to 1.86% in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Operating Margin are 1.86% (Q4 2025), 31.35% (Q3 2025), and 7.34% (Q2 2025).